Active Biotech - Rebound alter Schwede?!

0,13€

--
Korrektur zu #75
Aber kann ja noch werden.. ;)
 

Preclinical data with tasquinimod in MDS to be presented at ASH 2022
11/03/2022 | 09:01am EST
https://www.marketscreener.com/quote/stock/...d-at-ASH-2022-42194313/
Lund, November 3, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that an abstract with preclinical data on tasquinimod, a small molecule immunomodulator, in myelodysplastic syndrome (MDS), has been accepted for presentation at the 64th American Society of Hematology Annual Meeting in New Orleans, Louisiana, December 10-13, 2022 (ASH 2022). The ASH 2022 abstracts were released today, November 3rd, 2022.

The abstract, titled Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells will be presented by Dr. Manja Wobus, University Hospital Dresden, Germany.

The abstract is the result of a collaboration between Active Biotech and an academic group in Dresden, Germany which aims at addressing the unmet medical need to treat MDS. The presented data show that a subpopulation of mesenchymal stromal cells, i.e. CD271+ MSC’s, is responsible for the diminished hematopoietic support. Tasquinimod modulates the function of these cells and thereby enhances their potential to support hematopoiesis in vitro.

“These new preclinical results suggest that tasquinimod treatment has the potential to increase the hematopoiesis in MDS patients. We are exited to get the opportunity to present our data at such a prestigious conference as ASH, which manifests the external scientific interest in the project,” said Helén Tuvesson, CEO of Active Biotech.

Information on the presentation:

P 1753. Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271+ Mesenchymal Stromal Cells. Poster session 636. Myelodysplastic Syndromes – Basic and Translational: Poster I. Dec 10, 2022, 5:30-7:30 PM. Ernest N. Morial Convention Center, Hall D. Dr. M. Wobus et al., University Hospital Dresden, Germany.

The accepted abstract will be available on the ASH website from 9:00 am Eastern Daylight Time (2:00pm Central European Time) on November 3, 2022.

This information was submitted for publication, through the agency of the contact person set out above, at 15.00 pm CET on November 3, 2022.

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com  

Die HV lief offenbar gut... ;)
https://www.activebiotech.com/en/...l-meeting-of-active-biotech-ab-4/

+23% / auf nun 0,8 SKr.
https://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE877
 

Heute +34%
(Zwischenzeitlich schon ü 1,-Skr)
https://www.nasdaqomxnordic.com/shares/microsite?Instrument=SSE877

"Präklinische Tasquinimod-Daten bei Myelofibrose für mündliche Präsentation auf der ASH 2023 ausgewählt
02.11.2023 14:30 (MEZ)
Lund, 2. November 2023 – Active Biotech (NASDAQ STOCKHOLM: ACTI) gab heute bekannt, dass zwei Abstracts mit präklinischen Daten für Tasquinimod bei Myelofibrose und myelodysplastischem Syndrom (MDS) zur Präsentation auf der 65. Jahrestagung der American Society of Hematology in San Diego angenommen wurden , 9. – 12. Dezember 2023 (ASH 2023). Die Zusammenfassung, die die Wirkung von Tasquinimod bei Myelofibrose zeigt, wurde für einen mündlichen Vortrag ausgewählt. Die angenommenen Abstracts für ASH 2023 wurden heute, 2. November 2023, veröffentlicht.

Die Zusammenfassung mit dem Titel „ Präklinische Studien zum Nachweis der Wirksamkeit von Tasquinimod in Modellen fortgeschrittener myeloproliferativer Neoplasien (MPN) in der Blastenphase“ wird im Rahmen einer mündlichen Podiumspräsentation von Dr. Warren Fiskus, PhD MD Anderson Cancer Center, Texas, USA. Die Zusammenfassung ist ein Ergebnis der Zusammenarbeit zwischen Active Biotech und der Forschungsgruppe von Professor Kapil N. Bhalla bei MD Anderson und zielt in erster Linie darauf ab, die Mechanismen und Wirkungen von Tasquinimod bei Myelofibrose zu klären. Die vorzulegenden Daten belegen die Wirksamkeit von Tasquinimod als Monotherapie und in Kombination mit Erstlinientherapien in Modellen für fortgeschrittene Myelofibrose.

Darüber hinaus wird die Zusammenfassung mit dem Titel „ Tasquinimod verbessert die Erythropoese und mildert den Knochenverlust bei myelodysplastischen Mäusen“ als Poster von Dr. Manja Wobus, Universitätsklinikum Dresden, Deutschland. Die Zusammenfassung stammt aus unserer Zusammenarbeit mit Dr. Wobus in Dresden und zeigt den ersten Beweis einer In-vivo-Wirkung von Tasquinimod in einem Mausmodell von MDS durch eine deutliche Verbesserung der Anzahl roter Blutkörperchen und eine Verringerung des Knochenschwunds.

„Die vorzulegenden Daten legen nahe, dass die Behandlung mit Tasquinimod sowohl als Monotherapie als auch in Kombination mit anderen Therapien das Potenzial hat, eine breite Wirkung bei Myelofibrose und MDS zu erzielen. Wir freuen uns sehr und fühlen uns geehrt, die Gelegenheit zu haben, unsere Daten auf einer so prestigeträchtigen Veranstaltung präsentieren zu dürfen.“ Konferenz als ASH, was das externe wissenschaftliche Interesse an Tasquinimod im Krankheitsbereich zeigt“, sagt Helén Tuvesson, CEO von Active Biotech. Biotech.

Informationen zu den Vorträgen

Veröffentlichungsnummer: 741 Präklinische Studien zum Nachweis der Wirksamkeit von Tasquinimod in Modellen fortgeschrittener myeloproliferativer Neoplasien (MPN) in der Blastenphase, Warren Fiskus et al.
Sitzungsname: 631. Myeloproliferative Syndrome und chronische myeloische Leukämie: Grundlagen und Translation: Stromal-Immun- und Signalkontext
Sitzungsdatum: Montag, 11. Dezember 2023
Sitzungszeit: 10:30 – 12:00 Uhr
Präsentationszeit: 11:00 Uhr
Raum: San Diego Convention Center, Ballsaal 20AB

Veröffentlichungsnummer: 2798 Tasquinimod verbessert die Erythropoese und mildert den Knochenverlust bei myelodysplastischen Mäusen, Manja Wobus et al.
Sitzungsname: 604. Molekulare Pharmakologie und Arzneimittelresistenz: Myeloische Neoplasien: Poster II
Sitzungsdatum: Sonntag, 10. Dezember 2023
Präsentationszeit: 18:00 – 20:00 Uhr
Raum: San Diego Convention Center, Halls GH

Die Abstracts werden auf der Website von ASH verfügbar sein 09:00 Uhr Eastern Time (14:00 Uhr MEZ) am 2. November 2023..."
https://www.activebiotech.com/sv/mfn_news/...resentation-pa-ash-2023/


 

Q3/23
https://view.news.eu.nasdaq.com/...e3c7871a&lang=en&src=micro
"THIRD QUARTER IN BRIEF
Collaboration agreement for clinical study with tasquinimod in myelofibrosis signed (July 31)
Tasquinimod successfully completed dose optimization in patients with multiple myeloma and advances into the pre-planned expansion cohort (September 11)
Clinical safety and preclinical ocular biodistribution for laquinimod eye drops presented at the IOIS meeting is made available on Active Biotech’s website (September 13)

EVENTS AFTER THE END OF THE PERIOD
Preclinical data of tasquinimod in myelofibrosis awarded oral presentation at ASH 2023 (November 2)
The board of directors resolved on November 9, based on the authorization from the general meeting, to carry out a rights issue of approximately SEK 51 million (before issue costs) to secure financing of the ongoing and planned development programs for tasquinimod and laquinimod"
---

KE voraus...
https://view.news.eu.nasdaq.com/...1bdf828d&lang=en&src=micro
"The board of directors of Active Biotech AB (publ) (”Active Biotech” or the ”Company”) has, based on the authorisation from the general meeting, resolved on a rights issue of approximately SEK 51 million, before transaction costs. Not more than 113,633,436 new shares are issued through the rights issue. The subscription price amounts to SEK 0.45 per share and the right to subscribe for new shares shall vest in the Company’s shareholders with pre-emptive rights, whereby seven existing shares entitle to subscription for three new shares. The proceeds from the rights issue are intended to provide the Company with the financial stability needed to pursue the planned clinical research activities related to its prioritized programs, await the outcome of the ongoing clinical studies and conduct negotiations with partners. The Company has entered, free of charge, subscription commitments and issue guarantees of approximately SEK 27.6 million in relation to the rights issue..."
 

https://www.nasdaqomxnordic.com/aktier/...eId=1&Instrument=SSE877
Dieses Jahr schon über +100%

Hier mal die aktuelle Präsentation
https://www.activebiotech.com/wp-content/uploads/..._Presentation.pdf
Finanziell sieht das ziemlich schlecht aus (Seite 26)

aber besonders interessant, Seite 25
 

+27% auf 0,459 SEK
https://www.nasdaqomxnordic.com/aktier/...eId=1&Instrument=SSE877
--
https://www.activebiotech.com/en/mfn_news/...of-laquinimod-eye-drops/
"Active Biotech reports intriguing intraocular concentrations achieved in a clinical biodistribution study of laquinimod eye drops
Sep 10, 2024 08:30 (CEST) Regulatory
Lund, September 10 2024 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced an update to the ongoing clinical phase I biodistribution study of laquinimod eye drops in patients undergoing vitrectomy.

A proprietary formulation of laquinimod for corneal application was developed, taking the specific physico-chemical characteristics of this agent into account, to facilitate that a clinically relevant intraocular therapeutic concentration of laquinimod can be obtained.

The study, which is being conducted by principal investigator Professor Dr Nguyen at the Byers Eye Institute, Stanford University, Palo Alto, CA, US, aims to evaluate if laquinimod when administered as eye drops reaches the anterior and the posterior chambers of the eye, to support further development in patients with Uveitis.

During a 14-day preoperative administration of laquinimod as eye drops, all the three subjects in the first dose group received 0.6mg laquinimod once daily. All subjects, had significant concentrations of laquinimod in vitreous as well as in the anterior chamber fluid when sampled during surgery. This supports distribution of laquinimod from the cornea and sclera into the anterior chamber and onwards to the posterior parts of the eye. These data are also consistent with results previously obtained in rabbits and in an in vitro bovine corneal model of laquinimod penetration into the eye.

The bioanalytical results also show that administration of laquinimod eye drops leads to quantities of laquinimod in vitreous humour at therapeutically relevant concentrations, as determined from prior studies in multiple sclerosis patients. Anecdotally, a potent anti-inflammatory ocular effect of laquinimod was noted in the anterior chamber of one patient following 14-days of application as per the protocol, in absence of any concomitant corticosteroid treatment.

These initial findings are important to the further development of laquinimod for ocular disorders, as they unequivocally establish trans-corneal-scleral passage of laquinimod. The current study design involves enrolling additional patients at different dose-levels with top-line results expected in late 2024/early 2025.

“It is tremendously satisfying to learn that topical laquinimod, even at a low dose, can have the ability to penetrate into the anterior chamber, and more importantly, the vitreous of human eyes,” said Quan Đông Nguyen, MD, Professor of Ophthalmology, Medicine and Pediatrics at the Byers Eye Institute and the Stanford University School of Medicine. “The potential applications of a topical formulation and delivery that reaches the vitreous and possibly posterior segment are quite significant and can lead to very important and novel therapeutic implications. Our talented team at Byers and Stanford is very excited to proceed to complete the Study.”